Insider Trading April 2, 2026

Vita Coco CCO Executes $97,340 Share Sale Under Rule 10b5-1 Plan

Charles van Es sells 2,000 shares as analysts lift targets and company adds retail veteran to board

By Hana Yamamoto COCO
Vita Coco CCO Executes $97,340 Share Sale Under Rule 10b5-1 Plan
COCO

Charles van Es, Chief Commercial Officer at The Vita Coco Company, Inc. (NASDAQ: COCO), sold 2,000 shares on April 1, 2026, for $97,340 under a Rule 10b5-1 plan. The transaction follows a 61% 12-month stock run and comes amid analyst price-target increases and a board appointment for retail executive Shelley Broader. Analysis tools cited in filings suggest the shares may be trading above fair value.

Key Points

  • Charles van Es sold 2,000 Vita Coco shares on April 1, 2026, at $48.67 each, totaling $97,340 under a Rule 10b5-1 plan.
  • After the sale, van Es directly owns 77,691 shares; he also holds non-qualified options covering 232,267 underlying shares with exercise prices from $10.178 to $33.36 and expirations between 2030 and 2035.
  • Analysts have recently revised views upward - Evercore ISI raised its target to $70 (Outperform) citing strong scanner data; Morgan Stanley raised its target to $57 (Equalweight) and increased fiscal 2026-27 EBITDA estimates.

Charles van Es, the Chief Commercial Officer of The Vita Coco Company, Inc. (NASDAQ: COCO), reported the sale of 2,000 shares of common stock on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares changed hands at $48.67 apiece, producing a total transaction value of $97,340. The filing states the disposition was made pursuant to a Rule 10b5-1 trading plan.

Following this sale, van Es retains direct ownership of 77,691 shares of Vita Coco. The public company is currently valued at a market capitalization of $2.77 billion and trades at a price-to-earnings ratio of 45.34, per the data included in the filing.

The Form 4 also discloses that van Es holds a number of non-qualified stock options exercisable for common stock. Those options carry exercise prices that range from $10.178 to $33.36 and have expiration dates spanning from 2030 through 2035. The underlying securities represented by those options total 232,267 shares.

The insider sale occurs after the stock delivered a 61% return over the past year. At the same time, a valuation note in the filing references analysis indicating the shares are currently overvalued relative to their Fair Value.

Investors and analysts have recently adjusted their stances on the company. Evercore ISI increased its price target on Vita Coco to $70 while maintaining an Outperform rating, citing strong scanner data with sales rising 51.1% in early March and signaling improvements tied to promotional timing after discussions with management. Morgan Stanley also raised its target to $57 and kept an Equalweight rating, revising its fiscal 2026 and 2027 EBITDA estimates higher following the company’s fourth-quarter results. These actions reflect a more constructive near-term outlook from some sell-side analysts.

In addition to the analyst activity, Vita Coco announced the appointment of Shelley Broader to its Board of Directors. Broader brings extensive retail leadership experience, including executive roles at Chico’s FAS, Walmart EMEA, Walmart Canada, and Sweetbay Supermarkets, according to the announcement.

The combined disclosures in the Form 4 and the company’s recent announcements give investors several concrete points to weigh: an insider sale executed under a prearranged plan, material outstanding option positions held by an executive, upwardly revised analyst targets and estimates, and a board-level hire with deep retail experience. The filing also notes that investors can consult further research on the company, including comprehensive research reports available for COCO.

No additional explanatory commentary from van Es or from Vita Coco is included in the filing about the motivations for the sale beyond the Rule 10b5-1 designation. The documentation in the SEC filing remains the primary source of the transaction details.


What this means for market participants

For holders and observers of Vita Coco stock, the sale is notable for its timing amid recent analyst optimism and strong recent price performance. The company’s reported market metrics and disclosed option positions provide a clear snapshot of the executive’s remaining equity stake and potential future share issuance tied to option exercises.

Risks

  • Valuation risk - Analysis included in filings indicates the shares are trading above their Fair Value, suggesting limited margin for error for investors.
  • Concentration of potential future issuance - The existence of non-qualified options representing 232,267 underlying shares is a disclosed factor that could affect share count dynamics over time.
  • Dependence on near-term sales indicators - Analyst upgrades cited scanner data improvements and promotional timing as drivers of recent optimism, placing emphasis on these metrics for short-term performance.

More from Insider Trading

SoftVest Increases Stake in Cross Timbers Royalty Trust with $135k Purchase Apr 2, 2026 Gevo Officer Executes Small Share Sale, Exercises Options as Company Reports Strong Q4 Revenue Apr 2, 2026 Qualcomm Accounting Chief Sells Small Stake as Company Announces Buyback and Dividend Hike Apr 2, 2026 Sable Offshore CFO Sells $4.66 Million in Stock to Cover Tax Withholding After Restricted Shares Vest Apr 2, 2026 Steel Connect Sub Raises Stake in Spruce Power with $50,913 Buy Apr 2, 2026